Pionyr Immunotherapeutics
Stage
Corporate Minority | AliveTotal Raised
$345MValuation
$0000Last Raised
$275M | 3 yrs agoAbout Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Missing: Pionyr Immunotherapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pionyr Immunotherapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Pionyr Immunotherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pionyr Immunotherapeutics is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
1,568 items
Pionyr Immunotherapeutics Patents
Pionyr Immunotherapeutics has filed 7 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/18/2021 | 2/7/2023 | Clusters of differentiation, Cytokines, Immune system, Transcription factors, Immunology | Grant |
Application Date | 11/18/2021 |
|---|---|
Grant Date | 2/7/2023 |
Title | |
Related Topics | Clusters of differentiation, Cytokines, Immune system, Transcription factors, Immunology |
Status | Grant |
Latest Pionyr Immunotherapeutics News
Mar 23, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements. Gilead has waived its exclusive option to acquire Pionyr and certain other rights under
Pionyr Immunotherapeutics Frequently Asked Questions (FAQ)
Where is Pionyr Immunotherapeutics's headquarters?
Pionyr Immunotherapeutics's headquarters is located at 2 Tower Pl, South San Francisco.
What is Pionyr Immunotherapeutics's latest funding round?
Pionyr Immunotherapeutics's latest funding round is Corporate Minority.
How much did Pionyr Immunotherapeutics raise?
Pionyr Immunotherapeutics raised a total of $345M.
Who are the investors of Pionyr Immunotherapeutics?
Investors of Pionyr Immunotherapeutics include Gilead Sciences, Mission Bay Capital, SV Health Investors, Osage University Partners, OrbiMed Advisors and 6 more.
Who are Pionyr Immunotherapeutics's competitors?
Competitors of Pionyr Immunotherapeutics include Pathios Therapeutics, Neon Therapeutics, Forty Seven, NextCure, Harpoon Therapeutics and 10 more.
Compare Pionyr Immunotherapeutics to Competitors
OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.
ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies.
Immune-Onc provides biological services. The company helps cancer patients through cancer immunotherapy and biological development treatments including tumor microenvironment and immune suppressive pathways to develop biotherapeutics. Immune-Onc was founded in 2016 and is based in Palo Alto, California.
Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.
Epsilogen is engaged in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumors including greater potency, enhanced tumor access, and a long tissue half-life.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.